Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.

Published byBryan Barton Modified over 6 years ago

Similar presentations

Presentation on theme: "A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With."— Presentation transcript:

1 A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol  Christie M. Ballantyne, MD, Sukrut Shah, PhD, Aditi Sapre, PhD, Tanya B. Ashraf, BA, Sandra C. Tobias, PhD, Tayfun Sahin, PhD, MD, Ping Ye, PhD, MD, Yugang Dong, PhD, MD, Wayne Huey-Heng Sheu, MD, MS, PhD, Duk-Hyun Kang, PhD, Paulo Roberto Ferreira Rossi, MD, PhD, Yulia Moiseeva, MD, Ignacio Rodriguez Briones, MD, Amy O. Johnson-Levonas, PhD, Yale B. Mitchel, MD  American Journal of Cardiology  Volume 120, Issue 4, Pages (August 2017) DOI: /j.amjcard Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

2 Figure 1 Disposition of patients in treatment and reversal phases.
American Journal of Cardiology  , DOI: ( /j.amjcard ) Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

3 Supplementary Figure 1 Design of study (#NCT01860729).
American Journal of Cardiology  , DOI: ( /j.amjcard ) Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

4 Supplemental Figure 2 LS mean % change from baseline ± SE during the treatment and reversal phases. American Journal of Cardiology  , DOI: ( /j.amjcard ) Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

5 Supplementary Figure 3 Consistency of treatment effect on LDL-C (BQ) (A) and HDL-C (B) across patient subgroups defined by baseline characteristics. Results are plotted as the estimate (95% CI) of the difference in LS mean percent change from baseline for anacetrapib versus placebo group. American Journal of Cardiology  , DOI: ( /j.amjcard ) Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

6 Supplementary Figure 4 Systolic (A) and diastolic (B) BP (mm Hg) by week, all-patients-as-treated population in treatment phase. American Journal of Cardiology  , DOI: ( /j.amjcard ) Copyright © 2017 Merck Sharp & Dohme Corp, the Authors Terms and Conditions

Download ppt "A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With."

Similar presentations

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging.

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging.
Yale Mitchel, MD Cardiovascular Disease Department

Yale Mitchel, MD Cardiovascular Disease Department
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Dyslipidemia and Diabetic Macular Edema

Dyslipidemia and Diabetic Macular Edema
Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.

Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.
Volume 26, Issue 2, Pages e2 (August 2017)

Volume 26, Issue 2, Pages e2 (August 2017)
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis  Ashok.

Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis  Ashok.
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.
Meta-Analysis of Three Randomized Trials and Nine Observational Studies Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected.

Meta-Analysis of Three Randomized Trials and Nine Observational Studies Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected.
Modulation of High-Density Lipoproteins in a Population in Istanbul, Turkey, With Low Levels of High-Density Lipoproteins  Robert W. Mahley, MD, PhD,

Modulation of High-Density Lipoproteins in a Population in Istanbul, Turkey, With Low Levels of High-Density Lipoproteins  Robert W. Mahley, MD, PhD,
Copyright © 2002 American Medical Association. All rights reserved.

Copyright © 2002 American Medical Association. All rights reserved.
Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without.

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without.
Meta-Analysis of Dietary Glycemic Load and Glycemic Index in Relation to Risk of Coronary Heart Disease  Jia-Yi Dong, BSc, Yong-Hong Zhang, MD, PhD, Peiyu.

Meta-Analysis of Dietary Glycemic Load and Glycemic Index in Relation to Risk of Coronary Heart Disease  Jia-Yi Dong, BSc, Yong-Hong Zhang, MD, PhD, Peiyu.
Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.

Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.
Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the.

Contribution of Three-Dimensional Transesophageal Echocardiography to Diagnosis and Management of Thrombosis of a St. Jude Mechanical Prosthesis in the.
Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH 
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Similar presentations

Ads by Google